Login to Your Account

Ipsen Buys Botulinum Toxin Specialist Syntaxin for $206M

By Nuala Moran
Staff Writer

Monday, July 15, 2013

LONDON – The UK botulinum toxin specialist Syntaxin Ltd. is to be acquired by research partner and equity investor Ipsen SA in a deal that potentially is worth €158 million (US$205.8 million), with €28 million to be paid up front, and the remainder tied to development and commercialization milestones.

Separately, the shareholders are in line to receive any payments made on Syntaxin's Phase II lead program, a treatment for post-herpetic neuralgia, which is partnered with Allergan Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription